Gastroenterologia y hepatologia · 2025
Challenges in adherence to STRIDE-II: Perspectives from gastroenterologists and patients with inflammatory bowel disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carvajal Francisca, Herrera Karin, Núñez Paulina, Flores Lilian, Córdova Andrea, Pizarro Gonzalo, San Martín Pamela, Quera Rodrigo
Аннотация
INTRODUCTION: The treatment aims to achieve symptomatic remission, normalization of biomarkers such a fecal calprotectin, and endoscopic remission. Therefore, early recognition of inflammatory activity and timely therapeutic intervention are essential to improve the morbidity and mortality.
OBJECTIVE: Evaluate the adherence among gastroenterologists and the patients compliance with medical recommendations in the Inflammatory Bowel Disease Program at Clínica Universidad de los Andes PATIENTS AND METHODS: A retrospective study that included patients presenting with a flare confirmed by colonoscopy. Three follow-up stages were defined: Short-Term Control: symptomatic remission at 3months, Medium-Term Control: remission of fecal calprotectin as a biomarker (<250μg/g) between 4 and 6months, and Long-Term Control: endoscopic remission between 6 and 9months.
RESULTS: A total of 104 patients were evaluated, 64% of the cohort were females and a median age of 41years. Among them, 81% had Crohn's disease, with an inflammatory phenotype in 87% and colonic localization in 39%. The remaining 19% had ulcerative colitis with left-sided involvement in 50%. Ninety percent of the patients attended short term control with a symptomatic remission in 72%. Eighty-two percent attended medium term control, resulting in biomarker remission for 83% of them. Seventy seven percent attended long term control, achieving endoscopic remission in 59% of the cases.
CONCLUSION: The results indicate that our program achieves a physician adherence of over 90% to STRIDE-II, with patient's adherence to pharmacological therapy and follow up above 70%. Although these are high percentages, they are subject to improvement.
OBJECTIVE: Evaluate the adherence among gastroenterologists and the patients compliance with medical recommendations in the Inflammatory Bowel Disease Program at Clínica Universidad de los Andes PATIENTS AND METHODS: A retrospective study that included patients presenting with a flare confirmed by colonoscopy. Three follow-up stages were defined: Short-Term Control: symptomatic remission at 3months, Medium-Term Control: remission of fecal calprotectin as a biomarker (<250μg/g) between 4 and 6months, and Long-Term Control: endoscopic remission between 6 and 9months.
RESULTS: A total of 104 patients were evaluated, 64% of the cohort were females and a median age of 41years. Among them, 81% had Crohn's disease, with an inflammatory phenotype in 87% and colonic localization in 39%. The remaining 19% had ulcerative colitis with left-sided involvement in 50%. Ninety percent of the patients attended short term control with a symptomatic remission in 72%. Eighty-two percent attended medium term control, resulting in biomarker remission for 83% of them. Seventy seven percent attended long term control, achieving endoscopic remission in 59% of the cases.
CONCLUSION: The results indicate that our program achieves a physician adherence of over 90% to STRIDE-II, with patient's adherence to pharmacological therapy and follow up above 70%. Although these are high percentages, they are subject to improvement.